The hypothesis that innate immune activation contributes to AD pathogenesis has recently been supported by genome‐wide association studies which have identified several immune‐related gene variants, including Trem2 (Guerreiro et al, 2013) and Cd33 (Bradshaw et al, 2013), that modify the risk of developing AD. This evidence concerns the gene CD33 and Alzheimer disease.